Claudia Schmoor

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/292236/publications.pdf

Version: 2024-02-01

69 papers

3,765 citations

279798 23 h-index 54 g-index

75 all docs

75 docs citations

75 times ranked

5242 citing authors

#	Article	IF	CITATIONS
1	Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncology, The, 2009, 10, 855-864.	10.7	620
2	Assessment and comparison of prognostic classification schemes for survival data. , 1999, 18, 2529-2545.		584
3	How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care, 2018, 41, 356-363.	8.6	534
4	Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti–T-cell globulin ATG-Fresenius. Blood, 2011, 117, 6375-6382.	1.4	281
5	ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286). BMC Cancer, 2016, 16, 503.	2.6	234
6	RANDOMIZED AND NON-RANDOMIZED PATIENTS IN CLINICAL TRIALS: EXPERIENCES WITH COMPREHENSIVE COHORT STUDIES. Statistics in Medicine, 1996, 15, 263-271.	1.6	141
7	Sample size considerations for the evaluation of prognostic factors in survival analysis. , 2000, 19, 441-452.		89
8	Noninvasive Ventilation in COPD. Chest, 2011, 140, 939-945.	0.8	86
9	Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematology,the, 2017, 4, e293-e301.	4.6	83
10	EFFECTS OF COVARIATE OMISSION AND CATEGORIZATION WHEN ANALYSING RANDOMIZED TRIALS WITH THE COX MODEL. Statistics in Medicine, 1997, 16, 225-237.	1.6	72
11	Validation of existing and development of new prognostic classification schemes in node negative breast cancer. Breast Cancer Research and Treatment, 1997, 42, 149-163.	2.5	66
12	Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 × 2, Phase II Trial. Journal of Clinical Oncology, 2020, 38, 257-270.	1.6	63
13	Prognostic Factors Affecting Outcome after Allogeneic Transplantation for Hematological Malignancies from Unrelated Donors: Results from a Randomized Trial. Biology of Blood and Marrow Transplantation, 2012, 18, 1716-1726.	2.0	55
14	Competing Risks and Multistate Models. Clinical Cancer Research, 2013, 19, 12-21.	7.0	47
15	DECIDER: prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all-trans retinoic acid (ATRA) in patients >60Âyears with acute myeloid leukemia who are ineligible for induction chemotherapy, BMC Cancer, 2015, 15, 430.	2.6	47
16	Statistical issues in the analysis of adverse events in timeâ€toâ€event data. Pharmaceutical Statistics, 2016, 15, 297-305.	1.3	47
17	Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPAâ€REG OUTCOME trial. ESC Heart Failure, 2021, 8, 4517-4527.	3.1	46
18	Whole-brain irradiation with hippocampal sparing and dose escalation on metastases: neurocognitive testing and biological imaging (HIPPORAD) $\hat{a}\in$ a phase II prospective randomized multicenter trial (NOA-14, ARO 2015 $\hat{a}\in$ 3, DKTK-ROG). BMC Cancer, 2020, 20, 532.	2.6	43

#	Article	IF	Citations
19	Evidence from Nonrandomized Studies: A Case Study on the Estimation of Causal Effects. American Journal of Epidemiology, 2008, 167, 1120-1129.	3.4	41
20	Home Mechanical Ventilation for COPD: High-Intensity Versus Target Volume Noninvasive Ventilation. Respiratory Care, 2014, 59, 1389-1397.	1.6	41
21	Comparison of the cox model and the regression tree procedure in analysing a randomized clinical trial. Statistics in Medicine, 1993, 12, 2351-2366.	1.6	40
22	Impact of High-Intensity-NIV on the heart in stable COPD: a randomised cross-over pilot study. Respiratory Research, 2017, 18, 76.	3.6	40
23	On estimands and the analysis of adverse events in the presence of varying followâ€up times within the benefit assessment of therapies. Pharmaceutical Statistics, 2019, 18, 166-183.	1.3	38
24	Psychosocial distress and utilization of professional psychological care in cancer patients: An observational study in <scp>N</scp> ational <scp>C</scp> omprehensive <scp>C</scp> ancer <scp>C</scp> enters (<scp>CCC</scp> s) in <scp>G</scp> ermany. Psycho-Oncology, 2018, 27, 2847-2854.	2.3	37
25	Predictors of prognosis and treatment outcome in central retinal artery occlusion: local intra-arterial fibrinolysis vs. conservative treatment. Neuroradiology, 2015, 57, 1055-1062.	2.2	25
26	Capillary PO ₂ does not adequately reflect arterial PO ₂ in hypoxemic COPD patients. International Journal of COPD, 2017, Volume 12, 2647-2653.	2.3	23
27	Sex-Specific Differences in Outcome of Transcatheter or Surgical Aortic Valve Replacement. Canadian Journal of Cardiology, 2018, 34, 992-998.	1.7	23
28	A Wild Bootstrap Approach for the Aalen–Johansen Estimator. Biometrics, 2018, 74, 977-985.	1.4	22
29	Multicenter Experience With Mechanical Circulatory Support Using a New Diagonal Pump in 233 Children. Artificial Organs, 2018, 42, 377-385.	1.9	22
30	Volume–outcome relationship in transcatheter aortic valve implantations in Germany 2008–2014: a secondary data analysis of electronic health records. BMJ Open, 2018, 8, e020204.	1.9	22
31	Continuous nonâ€invasive <scp>PCO₂</scp> monitoring in weaning patients: <scp>T</scp> ranscutaneous is advantageous over endâ€tidal <scp>PCO₂</scp> . Respirology, 2017, 22, 1579-1584.	2.3	20
32	Learning Curves Among All Patients Undergoing Transcatheter Aortic Valve Implantation in Germany: A Retrospective Observational Study. International Journal of Cardiology, 2017, 235, 17-21.	1.7	20
33	Multicenter midterm followâ€up results using the gore septal occluder for atrial septal defect closure in pediatric patients. Catheterization and Cardiovascular Interventions, 2017, 89, E226-E232.	1.7	19
34	Correction of confounding bias in nonâ€randomized studies by appropriate weighting. Biometrical Journal, 2011, 53, 369-387.	1.0	16
35	Survival analysis for AdVerse events with VarYing followâ€up times (SAVVY): Rationale and statistical concept of a metaâ€analytic study. Biometrical Journal, 2021, 63, 650-670.	1.0	16
36	A note on estimating local recurrence rates in clinical trials on the treatment of breast cancer. Breast Cancer Research and Treatment, 1998, 49, 87-91.	2.5	14

#	Article	IF	CITATIONS
37	Post-Neoadjuvant Surveillance and Surgery as Needed Compared with Post-Neoadjuvant Surgery on Principle in Multimodal Treatment for Esophageal Cancer: A Scoping Review. Cancers, 2021, 13, 429.	3.7	13
38	Clinical evidence for respiratory insufficiency type II predicts weaning failure in long-term ventilated, tracheotomised patients: a retrospective analysis. Journal of Intensive Care, 2018, 6, 67.	2.9	12
39	Estimating and comparing adverse event probabilities in the presence of varying followâ€up times and competing events. Pharmaceutical Statistics, 2021, 20, 1125-1146.	1.3	12
40	Survival analysis for AdVerse events with VarYing follow-up times (SAVVY)â€"estimation of adverse event risks. Trials, 2021, 22, 420.	1.6	12
41	Randomized trial on the effect of radiotherapy in addition to 6 cycles CMF in node-positive breast-cancer patients., 2000, 86, 408-415.		11
42	Methodological arguments for the necessity of randomized trials in high-dose chemotherapy for breast cancer. Breast Cancer Research and Treatment, 1999, 54, 31-38.	2.5	10
43	A-Part Gel, an adhesion prophylaxis for abdominal surgery: a randomized controlled phase l–II safety study [NCT00646412]. Annals of Surgical Innovation and Research, 2015, 9, 5.	1.3	8
44	DECADE-pilot: decision aid, action planning, and follow-up support for patients to reduce the 10-year risk of cardiovascular diseases—a protocol of a randomized controlled pilot trial. Pilot and Feasibility Studies, 2017, 3, 32.	1.2	6
45	Relapse- and Immunosuppression-Free Survival after Hematopoietic Stem Cell Transplantation: How Can We Assess Treatment Success for Complex Time-to-Event Endpoints?. Biology of Blood and Marrow Transplantation, 2020, 26, 992-997.	2.0	6
46	Oronasal versus Nasal Masks for Non-Invasive Ventilation in COPD: A Randomized Crossover Trial. International Journal of COPD, 2021, Volume 16, 771-781.	2.3	6
47	Design aspects of COVIDâ€19 treatment trials: Improving probability and time of favorable events. Biometrical Journal, 2021, , .	1.0	6
48	Cytopathological Heterogeneity of Circulating Tumor Cells in Non-metastatic Esophageal Adenocarcinoma. Anticancer Research, 2020, 40, 5679-5685.	1.1	5
49	Efficacy of a short-term residential smoking cessation therapy versus standard outpatient group therapy (â€~START-Study'): study protocol of a randomized controlled trial. Trials, 2020, 21, 562.	1,6	5
50	Cytokine adsorption in patients with severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation: protocol for a randomised, controlled, open-label intervention, multicentre trial. BMJ Open, 2021, 11, e043345.	1.9	5
51	Prospective multicenter study of the breakable babystent for treatment of aortic coarctation in newborns and infants. Catheterization and Cardiovascular Interventions, 2022, 99, 1529-1537.	1.7	5
52	Portable NIV for patients with moderate to severe COPD: two randomized crossover trials. Respiratory Research, 2021, 22, 123.	3.6	4
53	Adverse event development in clinical oncology trials. Lancet Oncology, The, 2016, 17, e263-e264.	10.7	3
54	The Analysis of Adverse Events in Randomized Clinical Trials. , 2019, , 537-557.		3

#	Article	IF	Citations
55	Safety and tolerability of virucidal hand rubs: a randomized, double-blind, cross-over trial with healthy volunteers. Antimicrobial Resistance and Infection Control, 2015, 4, 37.	4.1	2
56	The COSTA Study: Sternal Closure in High-Risk Patients - A Prospective Randomized Multicenter Trial. Thoracic and Cardiovascular Surgeon, 2018, 66, 508-516.	1.0	2
57	Randomized Trial on GvHD Prophylaxis with or without Anti-Human T-Lymphocyte Immunoglobulin ATG-Fresenius (ATG-F) in Allogeneic Hematopoietic Cell Transplantation from Matched Unrelated Donors: Final Long-Term Results after 8.6 Years Median Follow-up. Blood, 2015, 126, 853-853.	1.4	2
58	Mastication after craniotomy: pilot assessment of postoperative oral health-related quality of life. Acta Neurochirurgica, 2022, 164, 1347-1355.	1.7	2
59	Randomized Phase II Study of All- <i>Trans</i> Retinoic Acid and Valproic Acid Added to Decitabine in Newly Diagnosed Elderly AML Patients (DECIDER trial): Predictive Impact of <i>TP53</i> Status. Blood, 2021, 138, 2380-2380.	1.4	2
60	Study Protocol of a Prospective Multicenter Study on Patient Participation for the Clinical Trial: Surgery as Needed Versus Surgery on Principle in Post-Neoadjuvant Complete Tumor Response of Esophageal Cancer (ESORES). Frontiers in Oncology, 2021, 11, 789155.	2.8	2
61	Feasibility of an Updated Randomised Controlled Trial on Surgical Urolithiasis Treatments: The Pilot Trial for the German Endoscopic versus Shock Wave Therapy Study (GESS). European Urology Focus, 2022, 8, 271-275.	3.1	1
62	Assessment and comparison of prognostic classification schemes for survival data. Statistics in Medicine, 1999, 18, 2529-2545.	1.6	1
63	Activity of Decitabine (DAC) Combined with All-Trans Retinoic Acid (ATRA) in Oligoblastic AML: Subgroup Analysis of a Randomized 2x2 Phase II Trial. Blood, 2020, 136, 9-10.	1.4	1
64	Validation of existing and development of new prognostic classification schemes in node negative breast cancer. Breast Cancer Research and Treatment, 1998, 48, 191-192.	2.5	0
65	Methodological aspects of the benefit assessment of medical interventions. Biometrical Journal, 2016, 58, 5-7.	1.0	0
66	A brief instrument to measure health-related quality-of-life in patients with bone metastasis: validation of the German version of Bone Metastases Quality-of-Life-10 (BOMET-QoL-10). Journal of Medical Economics, 2018, 21, 920-929.	2.1	0
67	Statistical models for complex data in clinical and epidemiological research. Biometrical Journal, 2020, 62, 528-531.	1.0	0
68	Postneoadjuvant surveillance and surgery as needed compared with postneoadjuvant surgery on principle in multimodal treatment for oesophageal cancer: a scoping review protocol. BMJ Open, 2021, 11, e044190.	1.9	0
69	Randomized Trial On GvHD Prophylaxis with or without Anti T Cell Globulin ATG Fresenius (ATG-F) in Allogeneic Hematopoietic Cell Transplantation From Matched Unrelated Donors: Updated Results and Evaluation of the European Group for Blood and Marrow Transplantation (EBMT) Risk Score Blood, 2012, 120, 3090-3090.	1.4	0